A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

GoodRx says that with the support of a healthcare team, a clear transition plan, and a few cost-saving tools, you can make ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Surgery risks have been highlighted in a new warning for users of popular diabetes and weight-loss drugs, including Ozempic ...

Insulin efsitora alfa (investigational once-weekly basal insulin): In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated ...

Novo Nordisk's late stage diabetes candidate semaglutide ... in controlling glucose levels and body weight. The phase 3 trial success over Lilly’s Trulicity (dulaglutide), an already-marketed ...

Ozempic (semaglutide) — The FDA approved Novo ... Sanofi’s injectable drug is indicated for Type 2 diabetes. Trulicity (dulaglutide) — The FDA approved the active ingredient in 2014, and ...

Weight-loss drugs and bariatric surgery both have an impact on cancer risk. A new study breaks down the link and how GLP-1 ...

which mimics the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) hormones, patients had a 20.2% reduction in weight by week 72 compared with a 13.7% reduction in ...

Eighteen studies examined the effect of GLP-1RAs on weight loss, glucose control ... known as Victoza), semaglutide (Ozempic or Wegovy), exenatide (Byetta or Bydureon), and dulaglutide (Trulicity).